J&J reveal long-term data for novel oral peptide
The new data suggests the IL-23 receptor antagonist peptide has…
The new data suggests the IL-23 receptor antagonist peptide has potential to address the high unmet need of a durable and convenient oral option in moderate-to-severe plaque psoriasis.